EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Verve Therapeutics's enterprise value is $-33.76 Mil.
Verve Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-217.67 Mil. Therefore, Verve Therapeutics's EV-to-EBITDA for today is 0.16.
The historical rank and industry rank for Verve Therapeutics's EV-to-EBITDA or its related term are showing as below:
VERV'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.54 Med: -3.01 Max: 0.27
Current: 0.18
During the past 5 years, the highest EV-to-EBITDA of Verve Therapeutics was 0.27. The lowest was -12.54. And the median was -3.01.
VERV's EV-to-EBITDA is ranked better than 87.77% of 466
companies
in the Biotechnology industry
Industry Median: 9.15
vs VERV: 0.18
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Verve Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Verve Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Verve Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Verve Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verve Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Verve Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Verve Therapeutics's EV-to-EBITDA falls into.
Verve Therapeutics's current Enterprise Value is $-33.76 Mil.
Verve Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-217.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Verve Therapeutics's PE Ratio for today is calculated as:
Verve Therapeutics's share price for today is $6.30.
Verve Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.120.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Verve Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Verve Therapeutics (Verve Therapeutics) Business Description
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VERV has been successfully added to your 